New research utilizing real-world patient data suggests that rosuvastatin, a widely prescribed statin for lowering high cholesterol, may be associated with a higher risk of kidney damage compared to its counterpart, atorvastatin. The study highlights concerns regarding hematuria, proteinuria, and even kidney failure, particularly when higher doses of rosuvastatin are administered.
Key Takeaways
- Rosuvastatin use is linked to an increased risk of hematuria (blood in urine), proteinuria (protein in urine), and kidney failure requiring replacement therapy when compared to atorvastatin.
- Higher doses of rosuvastatin appear to elevate these risks.
- A significant percentage of patients with advanced kidney disease were prescribed rosuvastatin doses exceeding FDA recommendations.
Understanding the Risks
Statins, including rosuvastatin, are crucial in managing high cholesterol, thereby reducing the risk of heart attacks and strokes. However, recent findings published in the Journal of the American Society of Nephrology indicate potential adverse effects on kidney function. The study analyzed electronic health records of over 152,000 rosuvastatin users and nearly 800,000 atorvastatin users over a median follow-up period of 3.1 years.
Study Findings
The research revealed that rosuvastatin users had an 8% higher risk of hematuria, a 17% higher risk of proteinuria, and a 15% higher risk of developing kidney failure requiring dialysis or transplantation compared to atorvastatin users. These risks were found to be more pronounced with higher doses of rosuvastatin. Alarmingly, the study also found that 44% of patients with advanced kidney disease were prescribed rosuvastatin doses higher than the FDA’s recommended maximum for individuals with impaired kidney function.
Expert Commentary
Lead researcher Jung-Im Shin, MD, PhD, of Johns Hopkins Bloomberg School of Public Health, stated, “Because rosuvastatin may cause proteinuria and hematuria, especially with high dose, high-dose rosuvastatin may not merit the risk—even if small—particularly for patients with advanced kidney disease.” This suggests that while rosuvastatin offers similar cardiovascular benefits to atorvastatin, the potential kidney risks, especially at higher dosages or in vulnerable patient populations, warrant careful consideration.
Sources
- Rosuvastatin Linked to Signs of Kidney Damage, Pharmacy Times.
- Real-world data links rosuvastatin to adverse effects on kidneys, Medical Xpress.
- Real world data links rosuvastatin with signs of kidney damage, Medical Dialogues.